• 1. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 2. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 3. Excited state character of Cibalackrot-type compounds interpreted in terms of Hückel-aromaticity: a rationale for singlet fission chromophore design?
  Weixuan Zeng,Ouissam El Bakouri,Henrik Ottosson Chem. Sci., 2021,12, 6159-6171
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Study of 3-Hydroxypyrrolidine-2-carboxylic Acid (CAS: 567-36-2) in Chemical Biology and Pharmaceutical Research

3-Hydroxypyrrolidine-2-carboxylic acid (CAS: 567-36-2), a cyclic β-amino acid derivative, has recently gained significant attention in chemical biology and pharmaceutical research due to its unique structural features and versatile biological activities. This compound serves as a crucial building block for the synthesis of various bioactive molecules, including peptidomimetics, enzyme inhibitors, and drug candidates. Recent studies have explored its potential applications in drug discovery, particularly in the development of novel therapeutics for neurological disorders, infectious diseases, and cancer.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the effectiveness of 3-hydroxypyrrolidine-2-carboxylic acid derivatives as selective inhibitors of bacterial aminoacyl-tRNA synthetases, offering a promising approach to combat antibiotic resistance. The researchers utilized structure-based drug design to optimize the compound's scaffold, achieving significant improvements in both potency and selectivity against pathogenic bacterial strains while maintaining low cytotoxicity in mammalian cells.

In neuropharmacology, a team from MIT reported in Nature Chemical Biology (2024) that 3-hydroxypyrrolidine-2-carboxylic acid derivatives can modulate glutamate receptor activity with unprecedented subtype specificity. This breakthrough suggests potential applications in treating neurodegenerative diseases such as Alzheimer's and Parkinson's, where glutamate excitotoxicity plays a key pathological role. The study employed advanced molecular modeling techniques combined with electrophysiological assays to elucidate the precise binding interactions.

Recent synthetic methodology developments have significantly improved access to enantiomerically pure 3-hydroxypyrrolidine-2-carboxylic acid. A 2024 publication in Organic Letters described a novel asymmetric catalytic hydrogenation protocol that achieves >99% ee with excellent yields, addressing previous challenges in the large-scale production of this valuable chiral building block. This advancement is particularly important for pharmaceutical applications where stereochemical purity is critical.

The compound's role in cancer research has also expanded, with multiple 2024 studies demonstrating its incorporation into proteolysis-targeting chimeras (PROTACs) targeting oncogenic proteins. These bifunctional molecules leverage 3-hydroxypyrrolidine-2-carboxylic acid as a linker that optimally positions the warhead and E3 ligase recruiter, resulting in improved degradation efficiency and pharmacokinetic properties compared to traditional linear linkers.

Ongoing clinical trials (as of Q2 2024) are evaluating several drug candidates containing the 3-hydroxypyrrolidine-2-carboxylic acid scaffold, including a novel DPP-4 inhibitor for type 2 diabetes and a PARP inhibitor for BRCA-mutated cancers. Preliminary results suggest favorable safety profiles and promising efficacy, though complete data are still forthcoming. These developments highlight the growing pharmaceutical relevance of this molecular framework.

Looking forward, researchers anticipate that further exploration of 3-hydroxypyrrolidine-2-carboxylic acid derivatives will yield additional therapeutic candidates, particularly in areas requiring precise molecular recognition such as protein-protein interaction inhibition and targeted protein degradation. The compound's versatility, combined with recent synthetic and analytical advancements, positions it as a key player in next-generation drug discovery efforts across multiple disease areas.

• 4298-08-2(trans-3-Hydroxyproline)
• 114717-04-3(L-Proline,3-hydroxy-5-methyl-, (2a,3b,5b)- (9CI))
• 114882-73-4(L-Proline,3-hydroxy-5-methyl-, (3S,5S)-)
• 114717-05-4(L-Proline,3-hydroxy-5-methyl-, (2a,3a,5a)- (9CI))
• 114717-06-5(L-Proline,3-hydroxy-5-methyl-, (3R,5R)-)
• 114717-07-6(D-Proline,3-hydroxy-5-methyl-, (2a,3b,5b)- (9CI))
• 114717-08-7(D-Proline,3-hydroxy-5-methyl-, (3R,5R)-)
• 61248-07-5(D-Proline, 3-hydroxy-5-methyl-, (3S,5S)-rel-)
• 61248-05-3(D-Proline, 3-hydroxy-5-methyl-, (3S,5R)-rel-)
• 61248-04-2(D-Proline, 3-hydroxy-5-methyl-, (3R,5S)-rel-)